Archive

Rehabilitation therapy for acute respiratory failure does not reduce hospitalization stay

by Bruce Sylvester: There is no decrease in hospital length of stay among patients hospitalized with acute respiratory failure who have received standardized rehabilitation therapy rather than usual… read more.

EHA 2016: Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Paul Richardson (Harvard Medical School, Boston, USA) and Professor Maria-Victoria Mateos (Salamanca, Spain) discuss the meta-analysis of OS in myeloma with maintenance therapy presented at ASCO and EHA this year, along with strategies for continuous therapies

Consolidation and maintenance therapy for multiple myeloma: is it the new standard?   Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year’s EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year's EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: A new multiple myeloma classification system that correlates to disease stage and prognosis

Hans Erik Johnsen, Aalborg University Hospital, Denmark. by Maria Dalby:  The gene expression profiles of myeloma plasma cells in the normal bone marrow can be used for defining… read more.

EHA 2016: Effect of response on associated costs and resource utilisation in MM. Professor Kwee Yong, University College Hospital, London, UK

EHA 2016: Smouldering Myeloma. Professor Maria-Victoria Mateos (Salamanca, Spain) discusses recent changes to the management of smouldering myeloma, her recommended work-up for these patients and the role of early treatment in this cohort.

EHA 2016: Molecular architecture of MM. Dr Brian Walker (University of Arkansas Medical School, Little Rock, USA) discusses his presentation in the education session on the molecular architecture of myeloma.

EHA 2016: What’s on the horizon in MM? Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) gives his take on what the future looks like for myeloma.

EHA 2016: Managing multiple myeloma in elderly/frail patients. Professor Antonio Palumbo (University of Torino, Italy) discusses the impact of age on outcomes (abstract E1295) and Professor Roman Hajek (University of Ostrava, Czech Republic) talks about preferred therapeutic strategies for elderly MM patients.

Managing multiple myeloma in elderly/frail patients   Although multiple myeloma is a disease of old age, elderly patients vary a great deal in terms of fitness and ability… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

EHA 2016: How monoclonal antibodies will change the treatment of multiple myeloma. Professor Antonio Palumbo (Torino, Italy) discuss the results of the CASTOR trial and Professor Meletios-Athanasios Dimopoulos (Athens, Greece) discussing POLLUX.

How monoclonal antibodies will change the treatment of multiple myeloma  by Maria Dalby   Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.